Dryneedlingtechniquesasatreatmentforimprovingdisabilityandpaininpatientswithdifferenttypesofheadache:Asystematicreviewandmeta-analysis

Headaches represent one of the most common neurological conditions worldwide, affecting between 8% and 73.3% of the global population depending on the population studied. These debilitating conditions significantly impair daily activities and quality of life, creating substantial personal and societal burdens. Headaches are broadly classified as primary (tension-type, migraine, and cluster headaches) or secondary (stemming from underlying medical conditions such as head injury or cervical spine disorders). While pharmacological treatments including analgesics, NSAIDs, and triptans remain common approaches, many patients seek non-pharmacological alternatives due to medication side effects, contraindications, or personal preferences.

Dry needling has emerged as a promising non-pharmacological intervention that involves inserting fine monofilament needles into myofascial trigger points without injecting any substance. The technique aims to elicit localized twitch responses, reduce muscle tension, improve blood flow, modulate pain pathways, and release endogenous pain-relieving substances. Despite preliminary evidence suggesting benefits for headache intensity, frequency, and disability, existing research has been scattered and limited in scope, necessitating a comprehensive synthesis to evaluate dry needling's true effectiveness across different headache types.

The researchers conducted a systematic review and meta-analysis following PRISMA guidelines and Cochrane Handbook standards, with a registered PROSPERO protocol (CRD42023440384). They comprehensively searched four major electronic databases—PubMed, EMBASE, Web of Science, and SCOPUS—from inception through May 2023 without language or date restrictions. After identifying 5,606 initial records and removing 1,302 duplicates, they screened 4,304 unique records. Through title/abstract screening and full-text assessment, they ultimately included 13 randomized controlled trials in the systematic review, with 10 RCTs suitable for meta-analysis.

The included studies were conducted across multiple countries including the United States, Turkey, Denmark, Iran, and India, with participant mean ages ranging from 28.2 to 44.7 years. Control groups varied and included sham interventions, physiotherapy, pharmacological treatments, or other standard care approaches. Two independent reviewers extracted data on study characteristics, participant demographics, and outcomes including disability scores, headache intensity, and headache frequency. Risk of bias was assessed using the Cochrane risk of bias tool version 2, revealing mixed quality across studies—six studies rated as low risk, one as high risk (Kamali et al., 2019), and five with some concerns.

The researchers used RevMan 5.4 software with random-effects models to compute standardized mean differences and mean differences, assessing heterogeneity through chi-square tests and I² statistics.

The meta-analysis revealed several significant findings across different follow-up timepoints. For disability scores, no significant difference emerged between dry needling and control groups after one week (SMD = -0.78, 95% CI [-1.9, 0.34], P = 0.17), though this data was highly heterogeneous (I² = 94%). However, after one month, two RCTs with 188 patients showed significant improvement in the dry needling group (SMD = -1.24, 95% CI [-1.61, -0.87], P < 0.00001) with homogeneous data (I² = 21%). This significant reduction persisted at three months (SMD = -1.63, 95% CI [-2.68, -0.58], P = 0.002), though heterogeneity increased (I² = 87%).

For headache intensity, post-intervention analysis of six RCTs with 381 patients showed significant reduction with dry needling (SMD = -1.39, 95% CI [-2.56, -0.23], P = 0.02), though with substantial heterogeneity (I² = 95%). At one month, five RCTs with 418 patients confirmed significant benefit (SMD = -1.12, 95% CI [-2.16, -0.09], P = 0.03), again with high heterogeneity (I² = 95%). Notably, between one week and two weeks, three RCTs with 191 patients found no significant difference (SMD = -0.25, 95% CI [-0.54, 0.03], P = 0.08). At three months, two RCTs with 188 patients demonstrated strong significant reduction (SMD = -1.52, 95% CI [-1.85, -1.19], P < 0.00001) with no heterogeneity (I² = 0).

For headache frequency, post-intervention analysis of two RCTs with 86 patients showed significant reduction (SMD = -1.51, 95% CI [-2.19, -0.83], P < 0.00001) with low heterogeneity (I² = 30%). At one month, three RCTs with 228 patients demonstrated significant benefit (MD = -1.63, 95% CI [-2.48, -0.78], P = 0.0002), though with moderate heterogeneity (I² = 76%) that resolved when excluding one study. At three months, two RCTs with 188 patients confirmed sustained significant reduction (MD = -2.05, 95% CI [-2.71, -1.4], P < 0.00001) with low heterogeneity (I² = 44%).

This meta-analysis provides important evidence that dry needling can be an effective non-pharmacological intervention for managing headaches, particularly for reducing headache intensity and frequency. The most robust and consistent benefits appear at one-month and three-month follow-ups, suggesting that dry needling's effects may require time to manifest fully or that cumulative treatments are needed. The lack of significant difference at very early timepoints (one week) but clear benefits at longer follow-ups indicates that clinicians and patients should not expect immediate dramatic improvements and should plan for a course of treatment.

The findings regarding disability scores are nuanced—while no significant benefit was seen at one week, significant improvements emerged at one and three months. This contrasts with some previous research and may reflect differences in included studies and measurement tools. The substantial heterogeneity observed in several analyses, particularly for headache intensity, highlights the diversity in study populations, intervention protocols, and control conditions across the existing literature. Several included studies combined dry needling with other interventions such as spinal manipulation or friction massage, making it difficult to isolate dry needling's specific contribution.

For patients, this research suggests that dry needling offers a viable alternative or complement to medication-based headache management, particularly for those preferring to minimize drug use. For clinicians, the evidence supports incorporating dry needling into multidisciplinary headache treatment protocols, with the understanding that benefits may become apparent after several sessions over weeks rather than immediately. The minimally invasive nature and generally good tolerability of dry needling make it an attractive option. However, the heterogeneous quality of existing studies and the inability to conduct secondary analyses on baseline changes due to limited data underscore the need for more standardized, high-quality research with uniform outcome measures and longer follow-up periods to better define optimal treatment protocols and patient selection criteria.